
PRCT Stock Forecast & Price Target
PRCT Analyst Ratings
Bulls say
PROCEPT BioRobotics is a promising surgical robotics company with a strong focus on advancing patient care in the urology field. Despite facing challenges such as increased competition from other BPH treatments and reimbursement changes, the company is expected to see steady revenue growth in the coming years, driven by its innovative technology and strong sales initiatives. The company's potential for longer-term growth and current undervaluation compared to its peers make it an attractive investment opportunity for those with a positive outlook on the healthcare sector.
Bears say
PROCEPT BioRobotics is facing headwinds in its growth trajectory due to competition from alternative BPH therapies, which may limit the company's ability to gain market share and drive procedure volumes. In turn, this could lead to lower sales and profitability, impacting the company's financials and ultimately its stock price. The recent sales force reorganization and inventory flush may continue to weigh on the company's performance in the short term. While the company has strong capital placements and high ASPs, there are concerns about the performance of handpiece sales and the steeper second-ramp implied. Additionally, the ongoing prostate cancer study may not have a significant impact on the company's stock in the near future.
This aggregate rating is based on analysts' research of PROCEPT BioRobotics Corp and is not a guaranteed prediction by Public.com or investment advice.
PRCT Analyst Forecast & Price Prediction
Start investing in PRCT
Order type
Buy in
Order amount
Est. shares
0 shares